Therapeutic application of induced pluripotent stem cells derived mesenchymal stromal cells for treatment of heart failure

Professor Tse, Hung Fat   (Project Coordinator (PC))

Professor Wang Jiwu   (Collaborator)

Dr Lian Qizhou   (Co-principal investigator)

Dr Liao Songyan   (Co-principal investigator)

Dr Ni Yuhui   (Collaborator)

60

2022-06-30

14057143

Therapeutic application of induced pluripotent stem cells derived mesenchymal stromal cells for treatment of heart failure

Cardiovascular diseases, Good Manufacturing Practice, Heart failure, Induced pluripotent stem cell, Mesenchymal stem cell

Regenerative MedicineCardiovascular Research

R7036-21

Research Impact Fund (RIF)

2021

On-going

(1) To establish a Master Cell Bank of current Good Manufacturing practice (cGMP) grade human induced pluripotent stem cell (hiPSC). (2) To develop analytics and process development of the differentiation protocol of cGMP-hiPSC into mesenchymal stromal cells (MSC), including substitution of cGMP-grade raw materials, standardization and validation of procedures, and characterization and quality control over the final product. (3) To establish a Master Cell Bank of hiPSC-MSC for preclinical and clinical investigation. (4) To investigate the safety and efficacy, and the optimal mode of delivery of hiPSC-MSCs for treatment of HF in a clinically-relevant large animal mode of ischemic cardiomyopathy (5) To perform the ""First-in-Human"" pilot trial of hiPSC-MSCs for treatment of HF in patients with end-stage ischemic cardiomyopathy (6) Generation of hiPSC-MSC-derived exosomes and examination of their safety and efficacy, and optimal mode of delivery for treatment of HF in a clinically-relevant large animal mode of ischemic cardiomyopathy.